Joining the dots for better liver cancer treatment

Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):74-75. doi: 10.1038/s41575-019-0238-3.
No abstract available

Publication types

  • Review

MeSH terms

  • Anilides / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / metabolism
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / genetics
  • Liver Neoplasms / metabolism
  • Nivolumab / therapeutic use
  • Patient Selection
  • Prognosis
  • Pyridines / therapeutic use
  • RNA-Seq
  • Ramucirumab
  • Single-Cell Analysis
  • Tumor Microenvironment / genetics
  • alpha-Fetoproteins / metabolism
  • beta Catenin / metabolism

Substances

  • Anilides
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Pyridines
  • alpha-Fetoproteins
  • beta Catenin
  • cabozantinib
  • Nivolumab
  • pembrolizumab